IL16 and prostate carcinoma: To be specific, there were no associations of genetic predisposition to levels of IL-1ß (OR, 1.14, 95% CI, 0.83, 1.51; P=0.480), IL-2a (OR, 1.00, 95% CI, 0.96, 1.03; P=0.781), IL-6ra (OR, 1.02, 95% CI, 1.00, 1.04; P=0.050), IL-8 (OR, 0.94, 95% CI, 0.85, 1.05; P=0.519), IL-16 (OR, 0.99, 95% CI, 0.96, 1.02; P=0.465), IL-17 (OR, 1.02, 95% CI, 0.90, 1.17; P=0.721), IL-18 (OR, 0.99, 95% CI, 0.95, 1.04; P=0.833) and IL-27 (OR, 0.99, 95% CI, 0.96, 1.01; P=0.434) with prostate cancer risk.